[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644599":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":42,"centralContacts":46,"locations":54,"responsibleParty":86,"collaborators":41,"id":88,"slug":41,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":41,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":41,"enrollmentInfo":96,"targetDuration":41,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":41,"overallStatus":57,"whyStopped":41,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Enicepatide Dose 1","EXPERIMENTAL","Participants will receive enicepatide Dose 1.",[13],"Combination Product: Enicepatide",{"label":15,"type":10,"description":16,"interventionNames":17},"Enicepatide Dose 2","Participants will receive enicepatide Dose 2.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Enicepatide Dose 3","Participants will receive enicepatide Dose 3.",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Placebo","PLACEBO_COMPARATOR","Participants will receive matching placebo.",[27],"Combination Product: Placebo",[29,38],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"COMBINATION_PRODUCT","Enicepatide","Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.",[9,15,19],[35,36,37],"RO7795068","CT-388","RG6640",{"type":30,"name":23,"description":39,"armGroupLabels":40,"otherNames":41},"Participants will receive matching placebo via SC injection as per the schedule in the protocol.",[23],null,[43],{"name":44,"affiliation":5,"role":45},"Clinical Trials","STUDY_DIRECTOR",[47,52],{"name":48,"role":49,"phone":50,"phoneExt":41,"email":51},"Reference Study ID Number: YC46401 https:\u002F\u002Fforpatients.roche.com No attachments to email below.","CONTACT","888-662-6728 (U.S. Only)","global-roche-genentech-trials@gene.com",{"name":53,"role":49,"phone":41,"phoneExt":41,"email":41},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[55,68,77],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":41},"The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)","RECRUITING","Ningbo","Zhejiang","315010","China",{"type":63,"coordinates":64},"Point",[65,66],121.54945,29.87819,{"lat":66,"lon":65},{"facility":69,"status":57,"city":70,"state":41,"zip":71,"country":61,"cosmosGeoPoint":72,"geoPoint":76,"contacts":41},"Peking University People's Hospital","Beijing","100044",{"type":63,"coordinates":73},[74,75],116.39723,39.9075,{"lat":75,"lon":74},{"facility":78,"status":57,"city":79,"state":41,"zip":80,"country":61,"cosmosGeoPoint":81,"geoPoint":85,"contacts":41},"Shanghai Fifth People's Hospital Affiliated to Fudan University","Shanghai","201304",{"type":63,"coordinates":82},[83,84],121.45806,31.22222,{"lat":84,"lon":83},{"type":87,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100644599",false,"NCT07670416","A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Body mass index (BMI) ≥24.0 kilograms per meter squared (kg\u002Fm\\^2) for participants with type 2 diabetes mellitus (T2DM)\n* BMI ≥28.0 kg\u002Fm\\^2 or BMI ≥24.0 and \\\u003C28.0 kg\u002Fm\\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* History of Type 1 diabetes mellitus (T1DM)\n* Obesity induced by other endocrinologic disorders\n* Any planned major medical procedure or surgery during the study\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder\n* Any lifetime history of suicide attempt\n* History of any hematologic conditions that may interfere with HbA1c measurement\n* History of acute or chronic pancreatitis or clinically significant gallbladder disease\n* Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization\n* Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer\n* Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1\u002FGIP RAs","ALL","18 Years",{"count":97,"type":98},300,"ESTIMATED","INTERVENTIONAL",[101],"PHASE3","The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.",[104,105,106],"Obesity","Overweight","Type 2 Diabetes Mellitus (T2DM)","2026-06-22",{"date":109,"type":110},"2026-06-26","ACTUAL",{"date":112,"type":98},"2026-06-25",{"date":114,"type":98},"2028-04-02",{"name":5,"class":6},3]